Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Pierce

Showing results (631-640 of 640) with videos related to

Pageof 64
Sort By:
You have reached the last page of results.This site can display upto 640 results.
Leukemia|March 25, 2017
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trialsG Montalban-Bravo, X Huang, K Naqvi, et al.
Journal of Medicinal Chemistry|June 11, 2004
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead findingPaolo Pevarello, Maria Gabriella Brasca, Raffaella Amici, et al.
Journal of Medicinal Chemistry|December 14, 2011
Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylaseKevin D Freeman-Cook, Paul Amor, Scott Bader, et al.
Aging Cell|March 12, 2025
Phosphorylation of an RNA-Binding Protein Rck/Me31b by Hippo Is Essential for Adipose Tissue AgingEunbyul Yeom, Hyejin Mun, Jinhwan Lim, et al.
Journal of Medicinal Chemistry|August 17, 2018
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|December 17, 2024
Towards standardization of person-reported outcomes (PROs) in pediatric diabetes research: A consensus reportKatharine Barnard-Kelly, David Marrero, Maartje de Wit, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|May 16, 2024
Towards the standardisation of adult person-reported outcome domains in diabetes research: A Consensus Statement development panelKatharine Barnard-Kelly, David Marrero, Maartje de Wit, et al.
Annals of Botany|April 9, 2010
Stomatal vs. genome size in angiosperms: the somatic tail wagging the genomic dog?J G Hodgson, M Sharafi, A Jalili, et al.
Journal of Medicinal Chemistry|May 13, 2017
Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug DesignKatherine L Lee, Catherine M Ambler, David R Anderson, et al.
Journal of Lipid Research|October 8, 2017
Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human PlasmaJohn A Bowden, Alan Heckert, Candice Z Ulmer, et al.
Pageof 64

Showing results (631-640 of 640) with videos related to

Sort By:
Pageof 64
You have reached the last page of results.This site can display upto 640 results.
Leukemia|March 25, 2017
A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trialsG Montalban-Bravo, X Huang, K Naqvi, et al.
Journal of Medicinal Chemistry|June 11, 2004
3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead findingPaolo Pevarello, Maria Gabriella Brasca, Raffaella Amici, et al.
Journal of Medicinal Chemistry|December 14, 2011
Maximizing lipophilic efficiency: the use of Free-Wilson analysis in the design of inhibitors of acetyl-CoA carboxylaseKevin D Freeman-Cook, Paul Amor, Scott Bader, et al.
Aging Cell|March 12, 2025
Phosphorylation of an RNA-Binding Protein Rck/Me31b by Hippo Is Essential for Adipose Tissue AgingEunbyul Yeom, Hyejin Mun, Jinhwan Lim, et al.
Journal of Medicinal Chemistry|August 17, 2018
Dual Inhibition of TYK2 and JAK1 for the Treatment of Autoimmune Diseases: Discovery of (( S)-2,2-Difluorocyclopropyl)((1 R,5 S)-3-(2-((1-methyl-1 H-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo[3.2.1]octan-8-yl)methanone (PF-06700841)Andrew Fensome, Catherine M Ambler, Eric Arnold, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|December 17, 2024
Towards standardization of person-reported outcomes (PROs) in pediatric diabetes research: A consensus reportKatharine Barnard-Kelly, David Marrero, Maartje de Wit, et al.
Diabetic Medicine : a Journal of the British Diabetic Association|May 16, 2024
Towards the standardisation of adult person-reported outcome domains in diabetes research: A Consensus Statement development panelKatharine Barnard-Kelly, David Marrero, Maartje de Wit, et al.
Annals of Botany|April 9, 2010
Stomatal vs. genome size in angiosperms: the somatic tail wagging the genomic dog?J G Hodgson, M Sharafi, A Jalili, et al.
Journal of Medicinal Chemistry|May 13, 2017
Discovery of Clinical Candidate 1-{[(2S,3S,4S)-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug DesignKatherine L Lee, Catherine M Ambler, David R Anderson, et al.
Journal of Lipid Research|October 8, 2017
Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950-Metabolites in Frozen Human PlasmaJohn A Bowden, Alan Heckert, Candice Z Ulmer, et al.
Pageof 64